Molecular imaging in thyroid cancer

Cancer Imaging

Volumn 10, Issue 1, 2010, Pages 1-7

  Heston, T F ^a,b   Wahl, R L ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b FCN Medical Testing Center   (United States)

Author keywords

FDG; Follicular thyroid cancer; Molecular imaging; Nuclear medicine; Papillary thyroid cancer; PET CT; Thyroid cancer

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GALLIUM 68; IODINE 124; IODINE 131; METHIONINE C 11; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; PENTETREOTIDE IN 111; PERTECHNETIC ACID TC 99M; RADIOACTIVE IODINE; SOMATOSTATIN RECEPTOR;

ASPIRATION BIOPSY; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; LYMPH NODE DISSECTION; MOLECULAR IMAGING; NECK DISSECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THYROGLOBULIN BLOOD LEVEL; THYROID CANCER; THYROID MEDULLARY CARCINOMA; THYROID NODULE; THYROID PAPILLARY CARCINOMA; THYROID SCINTISCANNING; THYROIDECTOMY; THYROTROPIN BLOOD LEVEL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; METHODOLOGY; PATHOLOGY; SCINTISCANNING; THYROID TUMOR;

HUMANS; MOLECULAR IMAGING; THYROID NEOPLASMS; THYROID NODULE; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 77952297724     PISSN: None     EISSN: 14707330     Source Type: Journal    
DOI: 10.1102/1470-7330.2010.0002     Document Type: Review

References (41)

1. American Cancer Society. Cancer facts & figures 2009. Atlanta: American Cancer Society; 2009. doi:10.2214/AJR.07.2848. PMid:18562736.
2. Ron E. Thyroid cancer incidence among people living in areas contaminated by radiation from the Chernobyl accident. Health Phys 2007; 93: 502-11. doi:10.1097/01.HP.0000279018.93081.29. PMid:18049226.
3. Naing S, Collins BJ, Schneider AB. Clinical behavior of radiation-induced thyroid cancer: factors related to recurrence. Thyroid 2009; 19: 479-85. doi:10.1089/thy.2008.0343. PMid:19226197.
4. Seaberg RM, Eski S, Freeman JL. Influence of previous radiation exposure on pathologic features and clinical outcome in patients with thyroid cancer. Arch Otolaryngol Head Neck Surg 2009; 135: 355-9. doi:10.1001/archoto.2009.13. PMid:19380356.
5. Ron E, Lubin JH, Shore RE, et al. Thyroid cancer after exposure to external radiation: a pooled analysis of seven studies. Radiat Res 1995; 141: 259-77. doi:10.2307/3579003. PMid:7871153.
6. Brownlie B, Mercer P, Turner J, Allison R. Thyroid malignancies: A New Zealand South Island thyroid clinic experience 1995-2006. N Z Med J 2008; 121: 36-45.
7. Weinstein SM. AIDS - pharmacologic update. J Intraven Nurs 1992; 15: 220-9.
8. Kim DL, Song KH, Kim SK. High prevalence of carcinoma in ultrasonography-guided fine needle aspiration cytology of thyroid nodules. Endocr J 2008; 55: 135-42. doi:10.1507/endocrj.K07-120. PMid:18219180.
9. Nam-Goong IS, Kim HY, Gong G, et al. Ultrasonography-guided fine-needle aspiration of thyroid incidentaloma: correlation with pathological findings. Clin Endocrinol (Oxf) 2004; 60: 21-8. doi:10.1046/j.1365-2265.2003.01912.x. PMid:14678283.
10. Liu Y. Clinical significance of thyroid uptake on F18-fluorodeoxyglucose positron emission tomography. Ann Nucl Med 2009; 23: 17-23. doi:10.1007/s12149- 008-0198-0. PMid:19205834.
11. Sapira JD. The art and science of bedside diagnosis. 1st ed. Baltimore: Williams & Wilkins; 1990.
12. Koike E, Noguchi S, Yamashita H, et al. Ultrasonographic characteristics of thyroid nodules: prediction of malignancy. Arch Surg 2001; 136: 334-7.
13. 201Tl scintigraphy in the follow-up of patients with differentiated thyroid carcinoma: diagnostic accuracy and clinical impact. Nucl Med Commun 2007; 28: 681-7. doi:10.1097/MNM.0b013e3282742090. PMid:17667746.
14. Wu HS, Huang WS, Liu YC, Yen RF, Shen YY, Kao CH. Comparison of FDG-PET and technetium-99m MIBI SPECT to detect metastatic cervical lymph nodes in well-differentiated thyroid carcinoma with elevated serum HTG but negative I-131 whole body scan. Anticancer Res 2003; 23: 4235-8.
15. 131I-Na scintigraphy in the detection of metastatic thyroid cancer. Eur J Nucl Med Mol Imaging 2004; 31: 491-8. doi:10.1007/s00259-003-1403-y. PMid:14666387.
16. Rufini V, Castaldi P, Treglia G, et al. Nuclear medicine procedures in the diagnosis and therapy of medullary thyroid carcinoma. Biomed Pharmacother 2008; 62: 139-46.
17. Castellani MR, Seregni E, Maccauro M, et al. MIBG for diagnosis and therapy of medullary thyroid carcinoma: Is there still a role? Q J Nucl Med Mol Imaging 2008; 52: 430-40.
18. Bozkurt MF, Ugur O, Banti E, Grassetto G, Rubello D. Functional nuclear medicine imaging of medullary thyroid cancer. Nucl Med Commun 2008; 29: 934-42. doi:10.1097/MNM.0b013e32830f4af2. PMid:18836370.
19. Kaltsas G, Korbonits M, Heintz E, et al. Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors. J Clin Endocrinol Metab 2001; 86: 895-902. doi:10.1210/jc.86.2.895. (Pubitemid 32207512)
20. Baudin E, Lumbroso J, Schlumberger M, et al. Comparison of octreotide scintigraphy and conventional imaging in medullary thyroid carcinoma. J Nucl Med. 1996; 37: 912-6.
21. Behr TM, Gratz S, Markus PM, et al. Anti-carcinoembryonic antigen antibodies versus somatostatin analogs in the detection of metastatic medullary thyroid carcinoma: are carcinoembryonic antigen and somatostatin receptor expression prognostic factors? Cancer 1997; 80(12 Suppl): 2436-57. doi:10.1002/(SICI)1097-0142(19971215)80:12+〈2436::AID-CNCR16〉3.0. CO;2-D.
22. Juweid M, Sharkey RM, Behr T, et al. Improved detection of medullary thyroid cancer with radiolabeled antibodies to carcinoembryonic antigen. J Clin Oncol 1996; 14: 1209-17.
23. Barbet J, Peltier P, Bardet S, et al. Radioimmunodetection of medullary thyroid carcinoma using indium-111 bivalent hapten and anti-CEA x anti-DTPA-indium bispecific antibody. J Nucl Med 1998; 39: 1172-8.
24. Bockisch A, Freudenberg LS, Schmidt D, Kuwert T. Hybrid imaging by SPECT/CT and PET/CT: proven outcomes in cancer imaging. Semin Nucl Med 2009; 39: 276-89. doi:10.1053/j.semnuclmed.2009.03.003. PMid:19497404.
25. 131I-SPECT/CT images obtained with an integrated system in the follow-up of patients with thyroid carcinoma. Eur J Nucl Med Mol Imaging 2004; 31: 1435-42.
26. Ingui CJ, Shah NP, Oates ME. Endocrine neoplasm scintigraphy: added value of fusing SPECT/CT images compared with traditional side-by-side analysis. Clin Nucl Med 2006; 31: 665-72. doi:10.1097/01.rlu.0000242599.22310.d2. PMid:17053381.
27. 18F-FDG uptake in the thyroid gland. J Nucl Med 2007; 48: 896-901. doi:10.2967/jnumed.106.039024. PMid:17504869.
28. Yasuda S, Shohtsu A, Ide M, et al. Chronic thyroiditis: Diffuse uptake of FDG at PET. Radiology 1998; 207: 775-8.
29. Kang BJ, O JH, Baik JH, Jung SL, Park YH, Chung SK. Incidental thyroid uptake on F-18 FDG PET/CT: correlation with ultrasonography and pathology. Ann Nucl Med 2009; 23: 729-37. doi:10.1007/s12149-009-0299-4. PMid:19768518.
30. Bae JS, Chae BJ, Park WC, et al. Incidental thyroid lesions detected by FDG-PET/CT: prevalence and risk of thyroid cancer. World J Surg Oncol 2009; 7: 63. doi:10.1186/1477-7819-7-63. PMid:19664272.
31. 18F]fluorodeoxyglucose-positron-emission tomography uptake in the thyroid gland in patients with cancer. AJNR Am J Neuroradiol 2009; 30: 1431-4. doi:10.3174/ajnr.A1559. PMid:19342543.
32. Chen W, Parsons M, Torigian DA, Zhuang H, Alavi A. Evaluation of thyroid FDG uptake incidentally identified on FDG-PET/CT imaging. Nucl Med Commun 2009; 30: 240-4. doi:10.1097/MNM.0b013e328324b431. PMid:19262287.
33. 18F-FDG PET/CT: clinical significance and improved characterization. J Nucl Med 2006; 47: 609-15.
34. Cohen MS, Arslan N, Dehdashti F, et al. Risk of malignancy in thyroid incidentalomas identified by fluorodeoxyglucose-positron emission tomography. Surgery 2001; 130: 941-6. doi:10.1067/msy.2001.118265. PMid:11742321.
35. Mansi L, Moncayo R, Cuccurullo V, Dottorini ME, Rambaldi PF. Nuclear medicine in diagnosis, staging and follow-up of thyroid cancer. Q J Nucl Med Mol Imaging 2004; 48: 82-95. (Pubitemid 39248297)
36. Larson SM, Robbins R. Positron emission tomography in thyroid cancer management. Semin Roentgenol 2002; 37: 169-74. doi:10.1016/S0037-198X(02)80035- 9.
37. Erdi YE, Macapinlac H, Larson SM, et al. Radiation dose assessment for I-131 therapy of thyroid cancer using I-124 PET imaging. Clin Positron Imaging 1999; 2: 41-6. doi:10.1016/S1095-0397(99)00004-7.
38. Grewal RK, Lubberink M, Pentlow KS, Larson SM. The role of iodine-124-positron emission tomography imaging in the management of patients with thyroid cancer. PET Clin 2007; 2: 313-20. doi:10.1016/j.cpet.2008.05.001.
39. Freudenberg LS, Antoch G, Jentzen W, et al. Value of (124)I-PET/CT in staging of patients with differentiated thyroid cancer. Eur Radiol 2004; 14: 2092-8. doi:10.1007/s00330-004-2350-0. PMid:15232708.
40. Dahnert W. Radiology review manual. Philadelphia: Lippincott Williams & Wilkins; 2003.
41. 18F- fluorodeoxyglucose positron emission tomography in preoperative assessment of cytologically indeterminate thyroid nodules. J Clin Endocrinol Metab 2007; 92: 4485-8. doi:10.1210/jc.2007-1043.